Hinge Health Inc. Class A Common Stock vs Li Auto Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Li Auto Inc trades at $11.25 (market cap $11.27B). The key difference: Li Auto Inc is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Li Auto Inc for 102 Days on average.
| HNGE | LI | |
|---|---|---|
Market Cap | $8.48B | $11.27B |
Volume | 879,799 | 3,921,121 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $22.72 |
52-Week Low | $31.17 | $10.69 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $8.10B | $673.48M |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Li Auto (LI) trades at $11.26, down 1.23% on the day and near its 52-week low, reflecting bearish technical signals and recent delivery declines. The company reported revenue of $112.31B in 2025 with a net income of $1.12B, but profitability metrics like net income margin and ROE remain negative. Recent news highlights challenges in China's EV market, with September 2026 deliveries of 31,817 vehicles showing moderation. Analyst consensus is mixed, with a $15.18 price target suggesting potential upside from current levels.
The outlook for LI is cautious due to intense competition and cash flow pressures, with net cash flow negative $9.0B in 2025. Investment opportunities include new model launches like the Li i9 SUV and global expansion, but risks from market volatility and execution missteps persist. Investors should weigh the company's solid balance sheet against near-term headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →